Literature DB >> 22459705

CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome.

Xiying Fan1, Bhaskar Upadhyaya, Liming Wu, Christopher Koh, Mónica Santín-Durán, Stefania Pittaluga, Gulbu Uzel, David Kleiner, Ester Williams, Chi A Ma, Aaron Bodansky, Joao B Oliveira, Pamela Edmonds, Ronald Hornung, Duane W Wong, Ronald Fayer, Tom Fleisher, Theo Heller, Calman Prussin, Ashish Jain.   

Abstract

X-linked hyper-IgM syndrome (XHM) is a combined immune deficiency disorder caused by mutations in CD40 ligand. We tested CP-870,893, a human CD40 agonist monoclonal antibody, in the treatment of two XHM patients with biliary Cryptosporidiosis. CP-870,893 activated B cells and APCs in vitro, restoring class switch recombination in XHM B cells and inducing cytokine secretion by monocytes. CP-870,893 infusions were well tolerated and showed significant activity in vivo, decreasing leukocyte concentration in peripheral blood. Although specific antibody responses were lacking, frequent dosing in one subject primed T cells to secrete IFN-g and suppressed oocyst shedding in the stool. Nevertheless, relapse occurred after discontinuation of therapy. The CD40 receptor was rapidly internalized following binding with CP-870,893, potentially explaining the limited capacity of CP-870,893 to mediate immune reconstitution. This study demonstrates that CP-870,893 suppressed oocysts shedding in XHM patients with biliary cryptosporidiosis. The continued study of CD40 agonists in XHM is warranted. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459705      PMCID: PMC3365556          DOI: 10.1016/j.clim.2012.01.014

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  37 in total

1.  Clinical spectrum of X-linked hyper-IgM syndrome.

Authors:  J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

Authors:  S P Schoenberger; R E Toes; E I van der Voort; R Offringa; C J Melief
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

3.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

Authors:  J P Ridge; F Di Rosa; P Matzinger
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

4.  Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM.

Authors:  A R Hayward; J Levy; F Facchetti; L Notarangelo; H D Ochs; A Etzioni; J Y Bonnefoy; M Cosyns; A Weinberg
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

Review 5.  CD40 ligand/CD40 deficiency.

Authors:  E Castigli; R Fuleihan; N Ramesh; E Tsitsikov; A Tsytsykova; R S Geha
Journal:  Int Arch Allergy Immunol       Date:  1995 May-Jun       Impact factor: 2.749

6.  Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice.

Authors:  M P Brown; D J Topham; M Y Sangster; J Zhao; K J Flynn; S L Surman; D L Woodland; P C Doherty; A G Farr; P K Pattengale; M K Brenner
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

7.  CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40.

Authors:  Y Yang; J M Wilson
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

Review 8.  The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.

Authors:  H D Ochs; D Hollenbaugh; A Aruffo
Journal:  Semin Immunol       Date:  1994-10       Impact factor: 11.130

9.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.

Authors:  M Cella; D Scheidegger; K Palmer-Lehmann; P Lane; A Lanzavecchia; G Alber
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.

Authors:  F Koch; U Stanzl; P Jennewein; K Janke; C Heufler; E Kämpgen; N Romani; G Schuler
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

Review 2.  Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.

Authors:  Xiangxue Meng; Bin Yang; Wen-Chen Suen
Journal:  Innate Immun       Date:  2017-11-13       Impact factor: 2.680

Review 3.  A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.

Authors:  William Checkley; A Clinton White; Devan Jaganath; Michael J Arrowood; Rachel M Chalmers; Xian-Ming Chen; Ronald Fayer; Jeffrey K Griffiths; Richard L Guerrant; Lizbeth Hedstrom; Christopher D Huston; Karen L Kotloff; Gagandeep Kang; Jan R Mead; Mark Miller; William A Petri; Jeffrey W Priest; David S Roos; Boris Striepen; R C Andrew Thompson; Honorine D Ward; Wesley A Van Voorhis; Lihua Xiao; Guan Zhu; Eric R Houpt
Journal:  Lancet Infect Dis       Date:  2014-09-29       Impact factor: 25.071

Review 4.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

5.  Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study.

Authors:  Yao Hao; Sayeda Yasmin-Karim; Michele Moreau; Neeharika Sinha; Erno Sajo; Wilfred Ngwa
Journal:  Phys Med Biol       Date:  2016-12-02       Impact factor: 3.609

6.  Molecular Basis of P131 Cryptosporidial-IMPDH Selectivity-A Structural, Dynamical and Mechanistic Stance.

Authors:  Kehinde F Omolabi; Clement Agoni; Fisayo A Olotu; Mahmoud E S Soliman
Journal:  Cell Biochem Biophys       Date:  2020-10-15       Impact factor: 2.194

7.  Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.

Authors:  Hayley Sparks; Gayatri Nair; Alejandro Castellanos-Gonzalez; A Clinton White
Journal:  Curr Trop Med Rep       Date:  2015-08-01

Review 8.  Prospects for immunotherapy and vaccines against Cryptosporidium.

Authors:  Jan R Mead
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.